SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1.

MLA

Shin, Jihoon, et al. “SARS-CoV-2 Infection Impairs the Insulin/IGF Signaling Pathway in the Lung, Liver, Adipose Tissue, and Pancreatic Cells via IRF1.” Metabolism: Clinical and Experimental, vol. 133, Aug. 2022, p. 155236. EBSCOhost, https://doi.org/10.1016/j.metabol.2022.155236.

APA

Shin, J., Toyoda, S., Nishitani, S., Onodera, T., Fukuda, S., Kita, S., Fukuhara, A., & Shimomura, I. (2022). SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism: Clinical and Experimental, 133, 155236. https://doi.org/10.1016/j.metabol.2022.155236

Chicago

Shin, Jihoon, Shinichiro Toyoda, Shigeki Nishitani, Toshiharu Onodera, Shiro Fukuda, Shunbun Kita, Atsunori Fukuhara, and Iichiro Shimomura. 2022. “SARS-CoV-2 Infection Impairs the Insulin/IGF Signaling Pathway in the Lung, Liver, Adipose Tissue, and Pancreatic Cells via IRF1.” Metabolism: Clinical and Experimental 133 (August): 155236. doi:10.1016/j.metabol.2022.155236.